Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: February 10, 2026
Reporting Period: Fourth quarter ended December 31, 2025
Context: The Company issued a press release containing preliminary, unaudited financial results for the fourth quarter of 2025. These results are incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The filing text references preliminary unaudited revenue for the fourth quarter ended December 31, 2025, but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this 8-K document. Investors must refer to the attached press release (Exhibit 99.1) for specific figures.
Material Changes
The filing does not contain specific data regarding material changes versus prior comparable periods. It only notes the issuance of preliminary estimates for the current quarter.
Guidance, Outlook, and Risks
- Unaudited Status: The preliminary estimates have not been audited, reviewed, or compiled by the Company's independent registered public accounting firm.
- Potential Variance: Actual results may differ from the preliminary estimates upon completion of year-end closing and auditing procedures.
- Legal Disclaimer: Information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue and financial figures not included in this summary.
- Verify the final audited results once the year-end closing and auditing procedures are complete.
- Confirm the status of the Interim Chief Financial Officer, Mark Frost, who signed the report.
- Monitor for any subsequent filings that may update or correct the preliminary estimates.